IRLA
IRulya Therapeutics Inc.- Healthcare
- Biotechnology
- $34M market cap
Forecast run · Oct 16, 2026Upside rank 218 of 3,181
Model Signal
ForecastQ Daily Probabilities
61.4%
77.7%
70.6%
Analyst Consensus
Recommendation2.80/5 Hold
Last price$33.23
Price target$70.00
Implied move+110.7%
Analysts10
ForecastQ Portfolios
IRLA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.